Hey Jesse...let me combine two birds with one stone. Your comments about the ascending triangle...A+. I don't use that type of tech/analysis but it appears sound. The 10-Q looks about as expected with little change from the comments of the annual meeting of a few months back.
Let me take polite issue with the secondary offering and the possibility of profit taking. You could very well be right but I prefer to see this as an underwriter getting preferred clients in at below the then current stock price as a form of "private placement done at a discount". Thereby selling to them with a built in profit. Who were these preferred clients? Who knows...but big boys to be sure.
I want to think that instead of them selling..........that they are in it for the long term and looking for much more than a 2 bagger.
But there will be those who will settle for that and be happy. I expect resistance and consolidation along with a rough climb between $8.50-10.50 to occur during the early part of 2014. If all goes well, $10.50 will be a distant memory after there are concrete results from the liver assay results along with analysts predicting future revenue growth.
Also, I expect analysts to become aware of the increasing flexibility and versatility of 3-d printing in the bio-tech field.
Am I dreaming? You tell me.
Always enjoy reading your comments and thoughts. They are always worthwhile....Philip
I think people are deflated regarding the statement of lack of revenue to date from recently signed agreements.
It should be noted that later in the report it says:
"We believe our cash and cash equivalents on hand as of September 30, 2013, together with amounts to be received from our collaborative research agreements"....
to be received would mean revenue is still due and expected from these agreements.
Sentiment: Strong Buy